Tirzepatide
Tirzepatide
# Tirzepatide
**Tirzepatide**, marketed under the brand name *Mounjaro*, is a medication primarily used for the treatment of type 2 diabetes. It belongs to the class of **dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists**. This medication helps regulate blood sugar levels and promotes weight loss as an additional benefit. Tirzepatide is administered via subcutaneous injection.
**Side effects** of Tirzepatide can include nausea, diarrhea, reduced appetite, and vomiting. Serious side effects are rare but can include pancreatitis, thyroid tumors, and allergic reactions. Its use is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma.
Tirzepatide was first approved for medical use in **2022** by the FDA and has since shown promise in managing obesity and other metabolic disorders in clinical trials. It is primarily used in conjunction with diet and exercise to improve glycemic control.
### Medical Name
**Tirzepatide**
### Formula
**C50H69N15O15**
### Trade Names
- Mounjaro
### Properties
- **Chemical Formula**: C50H69N15O15
- **Chemical Name**: Tirzepatide
### Asset
Upload an image or diagram relevant to Tirzepatide (e.g., its molecular structure or packaging) and set it as the asset.
Verbindungsinformationen